All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Monoclonal antibodies target antigens expressed by leukemic cells, making them more selective than chemotherapy. Antibodies can induce the innate immune response to destroy AML cells, or block key extracellular sites such as receptors to induce cancer cell death. In AML, target antigens include CD33, CD45, CD47, and CD123.